Circulating Tumor Cells Prognostic Technologies Market By Technology (Tumor Cells Enrichment, Tumor Cells Detection), By Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

The circulating tumor cells prognostic technologies market is set to reach US$ 12,443.3 Mn by 2026 from US$ 2,324.7 Mn in 2017 projecting excellent growth at a compounded annual growth rate (CAGR) of 20.8% during the forecast period from 2018 to 2026. As per the latest research findings of World Health Organization (WHO) 2018, cancer is the second largest cause of death globally with an estimation of 9.6 million deaths in 2018. Worldwide approximately 1 in 6 deaths occur due to cancer with 70% of the deaths occurring in low and middle income countries.

Cancer is a universal terminology for a group of diseases that affect different parts of the human body, it is also known as neoplasm or malignant tumor. Cancer is the rapid creation of abnormal cells which grow from their site of origin also invades other organs through a process known as metastasis which is usually facilitated by circulating tumor cells. Metastasis is the major cause of death in cancer patients.

"Technological advancement in cell enrichment segment to drive the circulating tumor cells market"

Currently the cell enrichment technology is dominating the circulating tumor cells prognostic technologies market. Recent technological advancement in cell enrichment techniques such as filtration, centrifugation and immunomagentic methods has resulted in improvised CTC’s functional characterization which finds prominence in disease diagnosis and target therapy. Other factor that drives the cell enrichment technology market is its increased adoption in biotechnology industries due to excellent accuracy and reliable methodology. Cell detection technology will foster impressive growth during the forecast period owing to the introduction of innovative and reproducible molecular biology technology such as isolation of CTC’s clusters from unprocessed blood. Standardization of optical methods in cell detection has resulted in conduction multicenter clinical trial studies.

"Rising incidence of breast cancer in women throughout the globe has resulted in positive traction for CTC’s prognostic technologies market"

Breast cancer is the most common type of cancer in women worldwide with variegated prevalence rate ranging from 19.3 per 100,000 women in East Africa to 89.7% per 100,000 women in Western European region. In the developing nations breast cancer is diagnosed in late stages which results in low survival rate. Researchers throughout the globe are developing biomarkers such as CK3-11D5 and HER2 for effective diagnosis of non-metastatic breast cancer in women. Prostate cancer will exhibit impressive growth during the forecast period on account of factors such as old age and testosterone imbalance in men. The prevalence rate is high in developed regions such as Europe and North America as people consume diet rich in fat such as dairy products and red meat which stimulates the excessive production of testosterone leading to onset of prostate cancer. Epic Sciences, Inc., has developed AR-V7 liquid biopsy test for the accurate prognosis of patients suffering with metastatic prostate cancer.

"Increasing number of patients suffering with cancer and increased funding in R&D to develop CTC’s prognostic technologies drive the Asia Pacific market"

North America currently holds the largest market in regional segment with 45% share. The key parameters responsible for its dominance are rising prevalence of cancer and increasing public health awareness resulting in early diagnosis. Domicile of key players such as AVIVA Biosciences and Epic Sciences, Inc., have catered to the prognostic needs of prostate and breast cancer in North America. According to World Health Organization (WHO) 2015 statistics, cancer is responsible for 20% of the deaths in Europe. Developed healthcare infrastructure and effective treatment guidelines for cancer propels the CTC’s prognostic technologies market in Europe. Asia Pacific serves as a lucrative market on account of factors such as increasing number of patients suffering with cancer and excellent research activities pertaining to development of biomarkers and antigens for cancer detection.

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Qualitative and quantitative market analysis were performed to determine the market estimation and compounded annual growth rate (CAGR). The market segment comprises of by technology, application and geography.

Market estimation and compounded annual growth rate (CAGR) for the report circulating tumor cells prognostic technologies was determined by applying the organic and inorganic market analysis. Technological innovations pertaining to the different types of CTC’s being applied for the prognosis of cancer is thoroughly discussed in the scope of the report. The key players spearheading the circulating tumor cells prognostic technologies market are Celula, Inc., Advanced Cell Diagnostics, Inc., Epic Sciences, Inc., AdnaGen GmbH, Fluxion Biosciences, Inc., AVIVA Biosciences Corporation, Rarecells USA, Inc., Vitatex, Inc., Silicon Biosystems S.p.A., and Veridex, LLC.